Atlanta, GA – Scibility Media – 11/06/2014.
This article discusses three companies: Medical Alarm Concepts Holdings Inc. (OTCMKTS:MDHI), Baxter International Inc. (NYSE:BAX) and DENTSPLY International Inc. (NASDAQ:XRAY)
Owner of patented MediPendant alarm device Medical Alarm Concepts Holdings Inc. (OTCMKTS:MDHI) has posted impressive earnings for the year ending June 30, 2014. Earnings for the year came at the back of a massive restructuring that so the company do away with its toxic debt obligations.
How Sales Jumped
Medical Alarm Concepts Holdings Inc. (OTCMKTS:MDHI) benefitted a great deal from a strategic change in the company’s business direction with more attention being paid to widespread distribution. The company claims it was done by dealing with few re-sellers and distributors which affected sales in the past. Going forward Medical Alarm Concepts Holdings Inc. (OTCMKTS:MDHI) expects to see stronger and sustainable growth in terms of margins and higher sales.
Net sales for the year grew by 101% to a high of $1.15 million up from $572,712 for the same period in 2013. A big chunk of the sales were generated from sales made to distributors as well as resellers and direct selling to consumers who continue to pay the company monthly monitoring services.
Medical Alarm Concepts Holdings Inc. (OTCMKTS:MDHI)’s costs of revenue for the year stood at $324,503 a 27% decline from a high of $41, 788 as of last year. A change in business direction allowed the company to generate more revenue from the monitoring of services to customers.
Gross Profit Grows
Gross profit for the year came in at $829, 190 up from $698,266 as of June 30, 2013. Revenue generated from monitoring services has been attributed to an increase in gross profit as they command high gross margins. A shift towards consumer marketing allowed the company to reduce its sale’s expenses to drop by $32,029 to a low of $212,133 from a high of $244,162 as of last year.
General and administrative expense more than doubled to a high of $1.7 million from a low of $628,273 last year. For the year ending June 30, 2014, Medical Alarm Concepts issued a total of 1,493,669 shares of common stock to management in pursuant of the Global Settlement Agreement consequently generating compensation expenses of $955, 948. A total of 50,000 shares were issued as compensation for consulting services offered, valued at $38,500.
Medical Alarm Concepts Holdings Inc. (OTCMKTS:MDHI) closed the year with net income amounting to $225, 041 a drop from high of $3.19 million last year. Cash equivalent as of close of business on June 30, 2014 stood at 7,673 up from 5,857 as of last year.
Baxter International Inc. (NYSE:BAX) has posted favorable results for its ongoing phase 2 study of subcutaneous immunoglobulin treatment at the biennial congress for immunodeficiency’s in Prague. The treatment targets patients with primary immunodeficiency that requires intravenous (IV) infusions after every three to four weeks.
Primary End Points Met
Baxter International Inc. (NYSE:BAX) reports that the study evaluated efficacy, safety, tolerability and pharmacokinetics of IGC 20% in European patients under the age of two years. Over the three months of the study, 48 participants were analyzed receiving 16% or IVIG 10%. The monthly doses were followed by weekly doses of IGSC 20% for 12 months.
The study successfully met its primary endpoints that measured the rate of validated acute serious bacterial infections according to Baxter International Inc. (NYSE:BAX). Only a single event was reported during the study period with IGSC 20% pneumonia of moderate severity, which equated to a low VASBI rate of 0.022/patient compared to specified threshold per patient of 0,0001
Infections rate with IGSC 20 percent without dose adjustment stood at 4.38/patient with mean serum IgG trough levels remaining comparable to IGIV 10 percent. Baxter did not report any serious events during the study period with the rate of AEs related to IGSC 20 percent for 17 of 48 patients coming in at 0.052/infusion.
Baxter International Inc. (NYSE:BAX) states that the majority of the AEs during the study turned out mild in severity with common events of erythema, swelling, pruritus and pain/discomfort. No cases of severe local or systemic AEs related to the treatment were reported with most of the infusions being completed successfully without any interruption.
Baxter BioScience vice president and MD, John Orloff, remains buoyant of the outcome of the results reiterating they only go to enhance and expand the company’s immunology portfolio. Once the phase 3 is carried out, data is to be presented for regulatory approval in the U.S and Europe. Baxter International Inc. (NYSE:BAX) hopes the study will be a revelation in the development of new therapeutic treatments alternatives for patients with immune deficiency disorders around the globe.
DENTSPLY International Inc. (NASDAQ:XRAY) Agrees To a Licensing Agreement with Ivoclar Vivadent Over Patent Infringement
Designer and developer of dental products DENTSPLY International Inc. (NASDAQ:XRAY) has reached a settlement with Ivoclar Vivadent over a patent infringement involving the sale of certain lithium silicate dental blanks. Ivoclar Vivadent had sought to stop the sale and importation of the products by DENTSPLY in a court filing. The settlement came as DENTSPLY agreed to enter into a licensing agreement with Ivoclar over products that were affected by the patents in question.
Sales Up 0.6%
Separately DENTSPLY International Inc. (NASDAQ:XRAY) posted a 0.6% increase in net sales for the three months ending September 30, 2014. Net sales came in at $708 million against last year same quarter sales of $704 million. Net sales excluding precious metal content came in at $682 million an increase of 1.8% from last year’s $669 million. DENTSPLY International Inc. (NASDAQ:XRAY) now expects to post full-year earnings per share of between $2.49 and $2.53.
Net income, on the other hand, came in at $75 million or $0.52 per diluted share down from a high of $80 million for last year same quarter.
EquiPress.com is a non-advertisement based network (currently in limited release) designed for investors to discover and communicate with publicly traded companies in real-time.
Sign-up for free now to experience the full benefits of EquiPress pre-launch.
Discover and communicate with companies you would otherwise never have seen based on your interests, company news, personalized news feeds, and one-on-one communications with no middle-men nor advertisements. Read our no advertisements pledge.
Can’t find your company on EquiPress? Send us an email to email@example.com and we will contact them for you.
Interested in a one month free trial? Get access to our private investor network, real-time news distribution, automatic disclaimers, corporate analytics, verified public profile, and industry-wide marketing of your corporate news.
Disclosure: EquiPress is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. EquiPress does not hold any equity or financial interest in any publicly traded company. EquiPress provides a uniform subscription based service to all publicly traded companies on a monthly basis at a rate of $495 to provide investor awareness. EquiPress receives only cash compensation from clients. Despite the relationship, EquiPress maintains a neutral stance (nonbiased) on any investment related opinions and exists solely for the purpose of allowing investors to communicate with the publicly traded companies in an effort to establish for themselves investment considerations. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor. Please visit www.equipress.com for complete risks and disclosures.